Dendritic cell-based vaccines in patients with hematological malignancies

被引：0

作者：

Brugger, W ^{[1
]}

Schneider, A ^{[1
]}

Schammann, T ^{[1
]}

Dill, P ^{[1
]}

Grünebach, F ^{[1
]}

Bühring, HJ ^{[1
]}

Kanz, L ^{[1
]}

Brossart, P ^{[1
]}

机构：

[1] Univ Tubingen, Med Ctr 2, Dept Hematol Oncol Immunol & Rheumatol, D-72076 Tubingen, Germany

来源：

HEMATOPOIETIC STEM CELLS 2000 BASIC AND CLINICAL SCIENCES | 2001年 / 938卷

关键词：

MUC1; AML; T-cell epitopes; dendritic cells; immunotherapy; leukemia;

D O I：

暂无

中图分类号：

Q2 [细胞生物学];

学科分类号：

071009 ; 090102 ;

摘要：

The epithelial mucin MUC1 is overexpressed on many epithelial malignancies as well as on some B-cell lymphomas and multiple myelomas. In the present study, we describe MUC1 expression also on primary AML blasts. To analyze the presentation of MUC1-derived HLA-A2 restricted peptides by primary AML blasts, we induced MUC1-specific cytotoxic T-lymphocytes (CTLs) in vitro using peptide pulsed dendritic cells from HLA-A2(+) healthy donors as antigen-presenting cells. These CTLs efficiently lysed primary AML blasts that constitutively expressed both MUC1 and HLA-A2. The specificity of the CTLs was confirmed in a cold target inhibition assay. Our data demonstrate that MUC1-derived peptides are tumor antigens in AML which could potentially be used for immunotherapeutic approaches.

引用

页码：359 / 363

页数：5

共 50 条

[41] Reengineering dendritic cell-based anti-cancer vaccines
Koski, Gary K.
Cohen, Peter A.
Roses, Robert E.
Xu, Shuwen
Czemiecki, Brian J.
[J]. IMMUNOLOGICAL REVIEWS, 2008, 222 : 256 - 276
[42] Dendritic cell-based vaccines Shining the spotlight on signal 3
Linette, Gerald P.
Carreno, Beatriz M.
[J]. ONCOIMMUNOLOGY, 2013, 2 (11)
[43] Application and preparation of dendritic cell-based vaccines for leukemia immunotherapy
[J]. 中国输血杂志, 2001, (S1) : 387 - 387
[44] Proving the principle: dendritic cell-based vaccines in urogenital cancers
Draube, Andreas
Klein-Gonzalez, Nela
von Bergwelt-Baildon, Michael
[J]. EXPERT REVIEW OF VACCINES, 2011, 10 (10) : 1355 - 1357
[45] Blood dendritic cells in patients with hematological malignancies
Weclawek-Tompol, J
Grotthus, E
Chybicka, A
Rybka, B
Ryczan, R
Noworolska-Sauren, D
[J]. EXPERIMENTAL HEMATOLOGY, 2005, 33 (07) : 102 - 102
[46] The role of molecular imaging in the development of dendritic cell-based cancer vaccines
Giovanni Lucignani
Maria Rescigno
[J]. European Journal of Nuclear Medicine and Molecular Imaging, 2005, 32 : 725 - 730
[47] Immune Evasion Pathways and the Design of Dendritic Cell-based Cancer Vaccines
Hanks, Brent A.
[J]. DISCOVERY MEDICINE, 2016, 21 (114) : 135 - 142
[48] Comparative evaluation of techniques for the manufacturing of dendritic cell-based cancer vaccines
Dohnal, Alexander Michael
Graffi, Sebastian
Witt, Volker
Eichstill, Christina
Wagner, Dagmar
Ul-Haq, Sidrah
Wimmer, Doris
Felzmann, Thomas
[J]. JOURNAL OF CELLULAR AND MOLECULAR MEDICINE, 2009, 13 (01) : 125 - 135
[49] Tumor vaccines and other dendritic cell-based immunotherapeutic approaches to cancer
De Gruijl, TD
[J]. ANNALS OF ONCOLOGY, 2005, 16 : 25 - 25
[50] Generation of dendritic cell-based vaccines under GMP in a university setting
Dilloo, D.
Ackermann, B.
Papewalis, C.
Fenk, R.
Kobbe, G.
Schott, M.
Meisel, R.
Eckert, H. G.
Bojar, H.
Prisack, B.
[J]. CYTOTHERAPY, 2006, 8 : 21 - 21

← 1 2 3 4 5 →